Table 4.
TKV and eGFR slopes by recommendation in Irazabal et al.,17
and treatment group
| Recommendation to exclude/include | Patients to exclude 1Aa/1B/2A/2Bb |
Patients to include 1C/1D/1E |
||
|---|---|---|---|---|
| Treatment | PLC n = 46 |
TLV n = 89 |
PLC n = 412 |
TLV n = 723 |
| TKV slope (%/yr) | 2.99 | 1.53 | 5.78 | 2.91 |
| 95% CI | 1.51, 4.48 | 0.63, 2.43 | 5.18, 6.39 | 2.55, 3.28 |
| Treatment effect (%/yr) | –1.44 | –2.79 | ||
| 95% CI | –2.91, 0.01 | –3.38, –2.20 | ||
| P value | 0.052 | <0.001 | ||
| Treatment | PLC n = 47 |
TLV n = 92 |
PLC n = 417 |
TLV n = 764 |
| eGFR slope (ml/min/1.73 m2 per yr) | –1.74 | –1.88 | –3.93 | –2.82 |
| 95% CI | –2.81, –0.67 | –2.44, –1.33 | –4.33, –3.53 | –3.05, –2.59 |
| Treatment effect (ml/min/1.73 m2 per yr) | –0.14 | 1.11 | ||
| 95% CI | –1.21, 0.93 | 0.71, 1.51 | ||
| P value | 0.79 | <0.001 | ||
CI, confidence interval; eGFR, estimated glomerular filtration rate (estimated by CKD-EPI equation); PLC, placebo treatment group; TKV, total kidney volume.
a
Because of the entry criteria, none of the patients enrolled into TEMPO 3:4 were class 1A.
b
Only 1 patient classified as 2B in this study.